Predict your next investment

Hedge Fund
kingdon.com

See what CB Insights has to offer

Investments

22

Portfolio Exits

11

About Kingdon Capital Management

Kingdon Capital Management LLC is a New York city-based hedge-fund which manages more than $5 billion in assets. The firm was founded by Mark Kingdon in 1993.

Kingdon Capital Management Headquarter Location

152 West 57th Street

New York, New York, 10019,

United States

212-333-0100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Kingdon Capital Management

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Kingdon Capital Management in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Kingdon Capital Management News

Imago BioSciences Raises USD 80 Million in Series C

Nov 19, 2020

Imago BioSciences, Inc., a clinical-stage biopharmaceutical company developing innovative treatments for myeloproliferative neoplasms, today announced the close of an USD 80 million Series C financing round. Farallon Capital Management, LLC led the round, with participation from new investors including funds and accounts advised by T. Rowe Price Associates, Inc., funds and accounts managed by Blackrock Advisors, LLC., Surveyor Capital (a Citadel company), Irving Investors and Kingdon Capital Management.

Kingdon Capital Management Investments

22 Investments

Kingdon Capital Management has made 22 investments. Their latest investment was in CeQur as part of their Series C - II on April 4, 2021.

CBI Logo

Kingdon Capital Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/13/2021

Series C - II

CeQur

$115M

Yes

4

11/19/2020

Series C

Imago BioSciences

$80M

Yes

7

6/18/2018

Convertible Note

Stealth BioTherapeutics

$100M

Yes

2

1/3/2017

Convertible Note

Subscribe to see more

$99M

Subscribe to see more

10

6/17/2015

Private Equity - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/13/2021

11/19/2020

6/18/2018

1/3/2017

6/17/2015

Round

Series C - II

Series C

Convertible Note

Convertible Note

Private Equity - II

Company

CeQur

Imago BioSciences

Stealth BioTherapeutics

Subscribe to see more

Subscribe to see more

Amount

$115M

$80M

$100M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

7

2

10

10

Kingdon Capital Management Portfolio Exits

11 Portfolio Exits

Kingdon Capital Management has 11 portfolio exits. Their latest portfolio exit was Imago BioSciences on July 16, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/16/2021

IPO

$991

1

2/15/2019

IPO

3

9/1/2017

Acquired

4

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

7/16/2021

2/15/2019

9/1/2017

00/00/0000

00/00/0000

Exit

IPO

IPO

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

3

4

10

10

Kingdon Capital Management Acquisitions

1 Acquisition

Kingdon Capital Management acquired 1 company. Their latest acquisition was US LEC on November 21, 2003.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

11/21/2003

Unattributed VC - II

$210M

Acquired

Date

11/21/2003

Investment Stage

Unattributed VC - II

Companies

Valuation

Total Funding

$210M

Note

Acquired

Sources

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.